YolTech Therapeutics Receives FDA Clearance for Phase 2/3 Study of YOLT-202 in AATD
YolTech Therapeutics received FDA approval for its IND application for YOLT-202, an in vivo gene-editing therapy for Alpha-1 Antitrypsin Deficiency. Interim data from an ongoing trial showed rapid increases in AAT levels to normal range with favorable safety.